Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.42 |
| ▸ | CFTR | P13569 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20996808 | 1.00 | GRM5 (0.42) | GRM5CFTRALDH1A1KDM4ENAAA | |
| SCHEMBL19505918 | 0.91 | CFTR (0.40) | GRM5CFTRALDH1A1KDM4EKMT2A | |
| SCHEMBL19475038 | 0.89 | L3MBTL1 (0.45) | GRM5ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL20996813 | 0.83 | POLB (0.32) | GRM5L3MBTL1 | |
| SCHEMBL19475321 | 0.83 | POLB (0.32) | GRM5L3MBTL1 | |
| SCHEMBL19475167 | 0.80 | ALDH1A1 (0.39) | GRM5ALDH1A1NAAAL3MBTL1KMT2A | |
| SCHEMBL19475165 | 0.80 | ALDH1A1 (0.39) | GRM5ALDH1A1NAAAL3MBTL1KMT2A | |
| SCHEMBL21917065 | 0.75 | LOXL2 (0.34) | GRM5CFTRALDH1A1KMT2A | |
| SCHEMBL21917067 | 0.75 | LOXL2 (0.34) | GRM5CFTRALDH1A1KMT2A | |
| SCHEMBL5647554 | 0.74 | L3MBTL1 (0.53) | L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | CCL11, MAN2A1, PREP | GRM5 2921/4885CFTR 546/4885ALDH1A1 2458/4885 |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | MASP2, MAN2A1, CCL11 | GRM5 3246/4885CFTR 740/4885ALDH1A1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.